Skip to main content
Top
Published in: Drugs & Aging 9/2013

01-09-2013 | Systematic Review

Medicare Part D and Long-Term Care: A Systematic Review of Quantitative and Qualitative Evidence

Authors: Camilla B. Pimentel, Kate L. Lapane, Becky A. Briesacher

Published in: Drugs & Aging | Issue 9/2013

Login to get access

Abstract

Background

In the largest overhaul to Medicare since its creation in 1965, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established Part D in 2006 to improve access to essential medication among disabled and older Americans. Despite previous evidence of a positive impact on the general Medicare population, Part D’s overall effects on long-term care (LTC) are unknown.

Objective

The purpose of this systematic review was to evaluate the literature regarding Part D’s impact on the LTC context, specifically costs to LTC residents, providers and payers; prescription drug coverage and utilization; and clinical and administrative outcomes.

Data sources

Four electronic databases [PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Health Business Fulltext Elite and Science Citation Index Expanded], selected US government and non-profit websites, and bibliographies were searched for quantitative and qualitative studies characterizing Part D in the LTC context. Searches were limited to studies that may have been published between 1 January 2006 (date of Part D implementation) and 8 January 2013.

Study selection

Systematic searches identified 1,624 publications for a three-stage (title, abstract and full-text) review. Included publications were in English language; based in the US; assessed Part D-related outcomes; and included or were directly relevant to LTC residents or settings. News articles, reviews, opinion pieces, letters or commentaries; case reports or case series; simulation or modeling studies; and summaries that did not report original data were excluded.

Study appraisal and synthesis methods

A standardized form was used to abstract study type, study design, LTC setting, sources of data, method of data collection, time periods assessed, unit of observation, outcomes and results. Methodological quality was assessed using modified criteria specific to quantitative and qualitative studies.

Results

Eleven quantitative and eight qualitative studies met inclusion criteria. In the seven years since its implementation, Part D decreased out-of-pocket costs among enrolled nursing home residents and potentially increased costs borne by LTC facilities. Coverage of prescription drugs frequently used by older adults was adequate, except for certain drugs and alternative formulations of importance to LTC residents. The use of medications that raise safety concerns was decreased, but overall drug utilization may have been unaffected. Although there was uncertain impact on clinical outcomes, quantitative studies demonstrated evidence of unintended health consequences. Qualitative studies consistently revealed increased administrative burden among providers.

Limitations

Empirical evidence of Part D’s LTC impact was sparse. Due to limitations in available types of data, quantitative studies were generically lacking in methodological rigor. Qualitative studies suffered from lack of clarity of reporting. As future studies use clinical Medicare data, study quality is expected to improve.

Conclusion

Although LTC-specific policies continue to evolve, it appears that the prescription drug benefit may require further modifications to more effectively provide for LTC residents’ unique medication needs and improve their health outcomes. Adjustments may be needed for Part D to be more compatible with LTC prescription drug delivery processes.
Appendix
Available only for authorised users
Literature
1.
go back to reference The Henry J. Kaiser Family Foundation. Medicare: a primer. Menlo Park: The Henry J. Kaiser Family Foundation; 2010. Report no.: 7615-03. The Henry J. Kaiser Family Foundation. Medicare: a primer. Menlo Park: The Henry J. Kaiser Family Foundation; 2010. Report no.: 7615-03.
2.
go back to reference Medicare Prescription Drug, Improvement, and Modernization Act of 2003, HR 1/Pub. L. No. 108-173, 117 Stat. 2066 (2003). Medicare Prescription Drug, Improvement, and Modernization Act of 2003, HR 1/Pub. L. No. 108-173, 117 Stat. 2066 (2003).
3.
go back to reference Edelman TS. Medicare prescription drug coverage for residents of nursing homes and assisted living facilities: special problems and concerns. Washington, DC: The Henry J. Kaiser Family Foundation; 2005. Report no.: 7342. Edelman TS. Medicare prescription drug coverage for residents of nursing homes and assisted living facilities: special problems and concerns. Washington, DC: The Henry J. Kaiser Family Foundation; 2005. Report no.: 7342.
5.
go back to reference Stuart B, Simoni-Wastila L, Baysac F, et al. Coverage and use of prescription drugs in nursing homes: implications for the Medicare Modernization Act. Med Care. 2006;44(3):243–9.PubMedCrossRef Stuart B, Simoni-Wastila L, Baysac F, et al. Coverage and use of prescription drugs in nursing homes: implications for the Medicare Modernization Act. Med Care. 2006;44(3):243–9.PubMedCrossRef
7.
go back to reference Jones AL, Dwyer LL, Bercovitz AR, et al. The National Nursing Home Survey: 2004 overview. Vital Health Stat 13. 2009;(167):1–155. Jones AL, Dwyer LL, Bercovitz AR, et al. The National Nursing Home Survey: 2004 overview. Vital Health Stat 13. 2009;(167):1–155.
8.
go back to reference Hing E, Bloom B. Long-term care for the functionally dependent elderly. Vital Health Stat 13. 1990;(104):1–50. Hing E, Bloom B. Long-term care for the functionally dependent elderly. Vital Health Stat 13. 1990;(104):1–50.
9.
go back to reference Requirements for States and Long Term Care Facilities, 42 C.F.R § 483.60 (2006). Requirements for States and Long Term Care Facilities, 42 C.F.R § 483.60 (2006).
12.
go back to reference Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.782 (2005). Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.782 (2005).
13.
go back to reference Lau DT, Briesacher BA, Touchette DR, et al. Medicare Part D and quality of prescription medication use in older adults. Drugs Aging. 2011;28(10):797–807.PubMedCrossRef Lau DT, Briesacher BA, Touchette DR, et al. Medicare Part D and quality of prescription medication use in older adults. Drugs Aging. 2011;28(10):797–807.PubMedCrossRef
14.
go back to reference Polinski JM, Donohue JM, Kilabuk E, et al. Medicare Part D’s effect on the under- and overuse of medications: a systematic review. J Am Geriatr Soc. 2011;59(10):1922–33.PubMedCrossRef Polinski JM, Donohue JM, Kilabuk E, et al. Medicare Part D’s effect on the under- and overuse of medications: a systematic review. J Am Geriatr Soc. 2011;59(10):1922–33.PubMedCrossRef
15.
go back to reference Polinski JM, Kilabuk E, Schneeweiss S, et al. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58(9):1764–79.PubMedCrossRef Polinski JM, Kilabuk E, Schneeweiss S, et al. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58(9):1764–79.PubMedCrossRef
16.
go back to reference Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCrossRef
17.
go back to reference Lohr KN, Carey TS. Assessing “best evidence”: issues in grading the quality of studies for systematic reviews. Jt Comm J Qual Improv. 1999;25(9):470–9.PubMed Lohr KN, Carey TS. Assessing “best evidence”: issues in grading the quality of studies for systematic reviews. Jt Comm J Qual Improv. 1999;25(9):470–9.PubMed
18.
go back to reference Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’ Handbook 4.2.2 [updated March 2004]. The Cochrane Library, Issue 1. Chichester: Wiley; 2004. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’ Handbook 4.2.2 [updated March 2004]. The Cochrane Library, Issue 1. Chichester: Wiley; 2004.
19.
go back to reference Moher D, Cook DJ, Jadad AR, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999;3(12):i–iv 1–98.PubMed Moher D, Cook DJ, Jadad AR, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999;3(12):i–iv 1–98.PubMed
20.
go back to reference Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedCrossRef Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedCrossRef
21.
go back to reference Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.PubMedCrossRef Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.PubMedCrossRef
22.
go back to reference Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D, nursing homes, and long-term care pharmacies. Washington, DC: Medicare Payment Advisory Commission; 2007. Report no.: 07-2. Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D, nursing homes, and long-term care pharmacies. Washington, DC: Medicare Payment Advisory Commission; 2007. Report no.: 07-2.
23.
go back to reference Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D and the nursing home setting. Gerontologist. 2008;48(4):432–41.PubMedCrossRef Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D and the nursing home setting. Gerontologist. 2008;48(4):432–41.PubMedCrossRef
24.
go back to reference Bazalo G, Weiss R. Measurement of unused medication in Medicare Part D residents in skilled nursing facilities. Consult Pharm. 2011;26(9):647–56.PubMedCrossRef Bazalo G, Weiss R. Measurement of unused medication in Medicare Part D residents in skilled nursing facilities. Consult Pharm. 2011;26(9):647–56.PubMedCrossRef
25.
go back to reference Bazalo G, Weiss RC. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Consult Pharm. 2012;27(4):269–73.PubMedCrossRef Bazalo G, Weiss RC. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Consult Pharm. 2012;27(4):269–73.PubMedCrossRef
26.
go back to reference US Department of Health and Human Services, Office of Inspector General. Availability of Medicare Part D drugs to dual-eligible nursing home residents. Washington, DC: US Department of Health and Human Services, 2008 Jun. Report no.: OEI-02-06-00190. US Department of Health and Human Services, Office of Inspector General. Availability of Medicare Part D drugs to dual-eligible nursing home residents. Washington, DC: US Department of Health and Human Services, 2008 Jun. Report no.: OEI-02-06-00190.
27.
go back to reference US Department of Health and Human Services, Office of Inspector General. Role of nursing homes and long term care pharmacies in assisting dual-eligible residents with selecting Part D plans. Washington, DC: US Department of Health and Human Services, 2008 Jun. Memorandum report no.: OEI-02-06-00191. US Department of Health and Human Services, Office of Inspector General. Role of nursing homes and long term care pharmacies in assisting dual-eligible residents with selecting Part D plans. Washington, DC: US Department of Health and Human Services, 2008 Jun. Memorandum report no.: OEI-02-06-00191.
28.
go back to reference Briesacher BA, Soumerai SB, Field TS, et al. Nursing home residents and enrollment in Medicare Part D. J Am Geriatr Soc. 2009;57(10):1902–7.PubMedCrossRef Briesacher BA, Soumerai SB, Field TS, et al. Nursing home residents and enrollment in Medicare Part D. J Am Geriatr Soc. 2009;57(10):1902–7.PubMedCrossRef
29.
go back to reference Briesacher BA, Soumerai SB, Field TS, et al. Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010;170(8):693–8.PubMedCrossRef Briesacher BA, Soumerai SB, Field TS, et al. Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010;170(8):693–8.PubMedCrossRef
30.
go back to reference Golden AG, Qiu D, Roos BA. Medication assessments by care managers reveal potential safety issues in homebound older adults. Ann Pharmacother. 2011;45(4):492–8.PubMedCrossRef Golden AG, Qiu D, Roos BA. Medication assessments by care managers reveal potential safety issues in homebound older adults. Ann Pharmacother. 2011;45(4):492–8.PubMedCrossRef
31.
go back to reference Huskamp HA, Stevenson DG, Keating NL, et al. Rejections of drug claims for nursing home residents under Medicare Part D. Health Aff (Millwood). 2008;27(2):560–7.CrossRef Huskamp HA, Stevenson DG, Keating NL, et al. Rejections of drug claims for nursing home residents under Medicare Part D. Health Aff (Millwood). 2008;27(2):560–7.CrossRef
32.
go back to reference Stevenson DG, Huskamp HA, Keating NL, et al. Medicare Part D and nursing home residents. J Am Geriatr Soc. 2007;55(7):1115–25.PubMedCrossRef Stevenson DG, Huskamp HA, Keating NL, et al. Medicare Part D and nursing home residents. J Am Geriatr Soc. 2007;55(7):1115–25.PubMedCrossRef
33.
go back to reference Stevenson DG, Keohane LM, Mitchell SL, et al. Medicare Part D claims rejections for nursing home residents, 2006 to 2010. Am J Manag Care. 2012;18(10):647–54.PubMed Stevenson DG, Keohane LM, Mitchell SL, et al. Medicare Part D claims rejections for nursing home residents, 2006 to 2010. Am J Manag Care. 2012;18(10):647–54.PubMed
34.
go back to reference West JC, Wilk JE, Rae DS, et al. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatry. 2010;71(4):400–10.PubMedCrossRef West JC, Wilk JE, Rae DS, et al. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatry. 2010;71(4):400–10.PubMedCrossRef
35.
go back to reference Wilk JE, West JC, Rae DS, et al. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiatr Serv. 2008;59(1):34–9.PubMedCrossRef Wilk JE, West JC, Rae DS, et al. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiatr Serv. 2008;59(1):34–9.PubMedCrossRef
36.
go back to reference Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14(11 Suppl):SP23–8.PubMed Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14(11 Suppl):SP23–8.PubMed
37.
go back to reference Raehl C, Maclaughlin E, Patry R, et al. Early implementation of Medicare Part D in urban and rural nursing facilities. Consult Pharm. 2007;22(9):744–53.PubMedCrossRef Raehl C, Maclaughlin E, Patry R, et al. Early implementation of Medicare Part D in urban and rural nursing facilities. Consult Pharm. 2007;22(9):744–53.PubMedCrossRef
38.
go back to reference Centers for Medicare and Medicaid Services. Impact of reassignment in the Part D program on health outcomes. Baltimore: Centers for Medicare and Medicaid Services; 2009. Centers for Medicare and Medicaid Services. Impact of reassignment in the Part D program on health outcomes. Baltimore: Centers for Medicare and Medicaid Services; 2009.
39.
go back to reference US Government Accountability Office. Medicare Part D: challenges in enrolling new dual-eligible beneficiaries. Washington, DC: US Government Accountability Office; 2007. Report no.: GAO-07-272. US Government Accountability Office. Medicare Part D: challenges in enrolling new dual-eligible beneficiaries. Washington, DC: US Government Accountability Office; 2007. Report no.: GAO-07-272.
40.
go back to reference US Government Accountability Office. Many factors, including administrative challenges, affect access to Part D vaccinations. Washington, DC: US Government Accountability Office; 2011. Report no.: GAO-12-61. US Government Accountability Office. Many factors, including administrative challenges, affect access to Part D vaccinations. Washington, DC: US Government Accountability Office; 2011. Report no.: GAO-12-61.
41.
go back to reference Huskamp HA, Oakman TS, Stevenson DG. Medicare Part D and its impact in the nursing home sector: an update. Washington, DC: Medicare Payment Advisory Commission; 2010. Report no.: 10-4. Huskamp HA, Oakman TS, Stevenson DG. Medicare Part D and its impact in the nursing home sector: an update. Washington, DC: Medicare Payment Advisory Commission; 2010. Report no.: 10-4.
42.
go back to reference Buchsbaum L, Varon J, Kagel E, et al. Perspectives on Medicare Part D and dual eligibles: key informants’ views from three states. Menlo Park, CA: The Henry K. Kaiser Family Foundation; 2007. Report no.: 7639. Buchsbaum L, Varon J, Kagel E, et al. Perspectives on Medicare Part D and dual eligibles: key informants’ views from three states. Menlo Park, CA: The Henry K. Kaiser Family Foundation; 2007. Report no.: 7639.
44.
go back to reference The Henry J. Kaiser Family Foundation. Medicare Part D prescription drug plan [PDP] availability in 2013. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2012. Publication no. 7426-09. The Henry J. Kaiser Family Foundation. Medicare Part D prescription drug plan [PDP] availability in 2013. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2012. Publication no. 7426-09.
45.
go back to reference Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.32; 2005. Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.32; 2005.
46.
go back to reference US Centers for Medicare and Medicaid Services, Survey and Certification Group. Nursing homes and Medicare Part D. Baltimore, MD: US Centers for Medicare and Medicaid Services; 2006. Memorandum reference no.: S&C-06-16. US Centers for Medicare and Medicaid Services, Survey and Certification Group. Nursing homes and Medicare Part D. Baltimore, MD: US Centers for Medicare and Medicaid Services; 2006. Memorandum reference no.: S&C-06-16.
48.
go back to reference Caffrey C, Sengupta M, Park-Lee E, et al. Residents living in residential care facilities: United States, 2010. NCHS Data Brief. 2012;91:1–8.PubMed Caffrey C, Sengupta M, Park-Lee E, et al. Residents living in residential care facilities: United States, 2010. NCHS Data Brief. 2012;91:1–8.PubMed
Metadata
Title
Medicare Part D and Long-Term Care: A Systematic Review of Quantitative and Qualitative Evidence
Authors
Camilla B. Pimentel
Kate L. Lapane
Becky A. Briesacher
Publication date
01-09-2013
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 9/2013
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-013-0096-6

Other articles of this Issue 9/2013

Drugs & Aging 9/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine